This study aimed to compare the efficacy and safety of EE/DRSP in a new flexible extended regimen that allowed the MIB with that of EE/DRSP in a conventional 28-day regimen in women with moderate-to-severe primary dysmenorrhoea.
Women with moderate-to-severe primary dysmenorrhoea-related pain received a flexible extended regimen with MIB or a conventional 28-day EE/DRSP. The primary outcome was the number of days with dysmenorrhea pain over 140 days. Secondary outcomes included other dysmenorrhoea-related pain outcomes, bleeding profile, satisfaction, and safety.
Overall, a total of 223 patients received study medication. There were significantly fewer days with dysmenorrhea pain with the flexibleMIB regimen than the conventional regimen and considerably fewer days with moderate dysmenorrhea pain and dysmenorrhea pain. Adverse events were similar with both regimens.
The study concluded that compared with the conventional regimen, the flexible extended regimen of EE/DRSP with MIB was associated with a reduction in days with dysmenorrhea pain in women with moderate-to-severe primary dysmenorrhoea. According to the Clinical Global Impression rating scale, the flexibleMIB regimen was also associated with more significant dysmenorrhea improvements and was generally well tolerated.
Reference: https://srh.bmj.com/content/38/2/94
